Life Sciences Psychedelics Biotech Psyence Group Inc. PSYGF has recently exported purified pharmaceutical grade psilocybin mushroom extract from its licensed and certified manufacturing facility in Southern Africa to its partner Contract Development & Manufacturing Organization (CDMO) in the UK.

In turn, the Good Manufacturing Practice (GMP) compliant pharmaceutical services company will use the imported psilocybin extract to develop standardized pharma-grade psilocybin and psilocin extracts that will be formulated into a finished product and will seek regulatory approval.

“We are incredibly proud to be one of the first companies to successfully export our pharmaceutical grade psilocybin to the UK, having recently completed exports to Portugal and Canada,” said Dr. Neil Maresky, CEO of Psyence.

The company operates one of the first federally licensed commercial psilocybin production facilities in the world. Located in Southern Africa, the center is certified and licensed for the cultivation, extraction and export of psilocybin mushrooms. Its production system is designed for continuous harvesting and has recently added an on-site laboratory for in-process analysis and extractions.

See also: Psychedelics company Filament signs a licensing deal with Psyence in the US, UK and EU

dr Maresky said the UK has the potential to become a leader in psychedelics research and that a secure supply of pharmaceutical-grade psilocybin will be “vital” to that.

Tony Budden, CSO of Psyence added, “Our on-site lab gives us the ability to produce pharma-grade psilocybin mushrooms and extracts for the legal psilocybin research markets worldwide. The systems and processes we have optimized ensure that we have been able to meet the UK’s stringent import regulations for this product.”

Photo: Benzinga edit with photo by Susie Hedberg and C4289N on Shutterstock.